jurnalul român de psihofarmacologie romanian journal of ...

9. Revicki DA. Pharmacoeconomic evaluation of treatments for refractory schizophrenia:
clozapine-related studies. J Clin Psychiatry 1999; 60(Supll. 1):7-11; discussion 28-30.
10. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness
clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4:345-355.
11. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a
comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol
2000; 15:245-255.
12. Glazer WM. Formulary decisions and health economics. J Clin Psychiatry 1998; 59(Suppl.
19):23-29.
13. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J
Psychiatry 1980; 137:383-386.
14. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 1989; 15:81-89.
15. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A.
Schizophrenia: manifestations, incidence and course in different cultures. A World Health
Organization ten-country study. Psychol Med Monogr Suppl 1992; 20:1-97.
16. Caldwell CB, Gottesman I. Schizophrenics kill themselves too: a review of risk factors for
suicide. Schizophr Bull 1990; 16:571-589.
17. Janca A, Hiller W. ICD-10 checklists – a tool for clinicians’ use of the ICD-10
classification of mental and behavioral disorders. Compr Psychiatry 1996; 37:180-187.
18. Desjarlais R, Eisenberg L, Good B, Kleinman A. World Mental Health: Problems and
Priorities in Low-Income Countries. New York: Oxford University Press 1995.
19. Carling K, Jacobson T. Modeling unemployment duration in a dependent competing risks
framework: identification and estimation. Lifetime Data Annal 1995; 1:111-122.
20. Leete E. A patient’s perspective on schizophrenia. New Dir Ment Health Service 1987;
34:81-90.
168